Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Drug Manufacturers - Specialty & Generic

Healthcare
$6.57 -1.07%

-$0.06 today

Market cap
$98.52M
Beta
0.10
P/E (TTM)
-11.5
EPS (TTM)
-$0.48
52W Low $1.85High $6.61

Volume 0.16M

Average 0.97M

CPIX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Cumberland Pharmaceuticals Inc.NASDAQ: CPIX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 78.8%

Gross margin was 78.8% in Q1 FY2026, down 9.0 pp from a year earlier. On a trailing-twelve-month basis it was 82.9%, down 1.4 pp year over year. Over 3 fiscal years it widened by 6.7 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
78.8%-4.8 pp QoQ
Last fiscal yearDec 2025
85.0%+2.4 pp YoY
LTMMar 2026
82.9%-1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-9.0 pp——
1 year+2.4 pp——
3 years+6.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
85.0%
Year-over-year change
+2.4pp

Gross Margin vs competitors

How CPIX compares with its peers on the latest reported figures

  • CPIX's LTM Mar 2026 gross margin of 82.9% is the highest of the 3 companies compared; the peer median is 53.6%.
  • Its year-over-year change of -1.4 pp is the 2nd highest of 3, against a peer median of -12.4 pp.
  • Over three fiscal years its change of +6.7 pp compares with a peer median of -15.2 pp.
CPIX Competitors Peer median
Gross Margin for CPIX and competitors
Company Period LTM level YoY 3-year change
CPIXCumberland Pharmaceuticals Inc.LTM Mar 202682.9% -1.4 pp+6.7 pp
CELUCelularity Inc.LTM Dec 202576.0% +3.7 pp+85.4 pp
DYAIDyadic International, Inc.LTM Mar 202631.3% -28.4 pp-115.8 pp
LTRNLantern Pharma Inc.FY2025— ——
Peer median (excluding CPIX) 53.6%-12.4 pp-15.2 pp

Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue35.99M42.01M39.55M37.87M44.52M
Cost of Revenue8.81M9.12M6.07M6.59M6.67M
Gross Profit27.17M32.89M33.49M31.28M37.85M
Gross Margin75.5%78.3%84.7%82.6%85.0%
Research & Development5.68M6.69M5.83M4.82M5.57M
Selling, General & Admin24.8M26.84M29.1M28.15M31.05M
Operating Expenses34.85M38.6M43.04M37.71M40.65M
Depreciation & Amortization4.61M5.33M8.1M6.04M5.29M
EBITDA(857.83K)332.92K2.49M182.42K2.96M
EBITDA Margin-2.4%0.8%6.3%0.5%6.6%
Operating Income(7.68M)(5.7M)(9.55M)(6.43M)(2.79M)
Operating Margin-21.3%-13.6%-24.2%-17.0%-6.3%
Interest Income26.08K98.41K286.85K334.44K476.75K
Interest Expense98.03K586K667.86K605.51K495.99K
Other Income / Expenses2.12M123.74K3.27M(33.98K)(32.46K)
Income Before Tax(5.56M)(5.58M)(6.28M)(6.47M)(2.82M)
Pre-Tax Margin-15.5%-13.3%-15.9%-17.1%-6.3%
Income Tax Expense34.89K68.85K45.77K(22.67K)40.26K
Net Income(3.51M)(5.57M)(6.28M)(6.48M)(2.84M)
Net Margin-9.7%-13.3%-15.9%-17.1%-6.4%
EPS (Basic)(0.24)(0.38)(0.44)(0.46)(0.19)
EPS (Diluted)(0.24)(0.38)(0.44)(0.46)(0.19)
Weighted Avg Shares14.9M14.56M14.3M14.06M14.96M
Weighted Avg Shares (Diluted)14.9M14.56M14.3M14.06M14.96M

Cumberland Pharmaceuticals Inc.

NASDAQ:CPIX

Intrinsic Alpha fair value

Locked

Current Price

$6.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.